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S308 Poster Session IIcells on day 14 after allo-BMT, revealed that these cells displayed sub-
stantial levels of cell-surface P-selectin ligands as defined by positive
staining with recombinant P-selectin-IgG-Fc fusion protein at levels
similar to those foundonWTTcells, suggesting that althoughabsence
of P-selectin on host tissues may ameliorate GVHD, multiple donor
leukocyte P-selectin ligands interact meaningfully with P-selectin.
Our studies suggest that P-selectin may be required for trafficking
into inflamed tissues but not SLO, and that donor T cells may utilize
multiple P-selectin ligands apart from PSGL1 to interact with P-se-
lectin and traffic into inflamed tissues during GVHD.409
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Preparative regimens incorporating antithymocyte globulin
(ATG) have been shown to decrease the incidence of both acute
and chronic graft-versus-host disease (aGVHD and cGVHD). It is
less clearwhether priorATGinfluences the patternof onset, duration
of treatment and graft-versus-malignancy(GVM) effect of cGVHD.
Between 1999 and 2008, 538 patients (pts) with hematologic malig-
nancy aged 18–66 years (median 46) received blood cell (n5 440,
82%) or marrow transplants after conditioning with Flu 50 mg/m2
daily  5 and IV Bu 3.2 mg/kg daily  4. Two hundred and thirty-
four (43%) had additional total body irradiation (TBI) 200 cGy 2.
GVHD prophylaxis was cyclosporin A, methotrexate and Thymo-
globulin (Genzyme) 4.5 mg/kg total dose. Donors werematched sib-
lings in 299 (56%), mismatched related in 27(5%), 10/10 matched
unrelated in 146 (27%) and mismatched unrelated in 66(12%).
Two hundred and fifty-six pts (48%) had low-risk (LR, acute leuke-
mia CR1/CR2, CML CP1) disease. Incidence of aGVHD grade II-
IV, aGVHD grade III-IV and cGVHD (at 2 years) was 24%, 10%
and 56% respectively. Of 474 pts surviving .100days, 371 (78%)
had no or grade I aGVHD, 167 (45%) of whom developed cGVHD.
Of the 103 pts with prior grade II-IV aGVHD, 4 died before d126 of
late effects of aGVHD (and are excluded from the analysis of the no
cGVHD group), 17 survived without cGVHD, 21 developed
cGVHD after discontinuing treatment for aGVHD (‘‘quiescent’’
cGVHD) of whom 2 (10%) died without relapse. Sixty-one devel-
oped cGVHD before completing treatment for aGVHD grade II-
IV, defined as ‘‘progressive’’ cGVHD (pcGVHD) for the purpose
of this study. There were therefore 188 pts with ‘‘non-progressive’’
cGVHD (npcGVHD) (167 de novo plus 21 ‘‘quiescent’’) and 221
with no cGVHD. At follow-up of survivors of 14–124 months (me-
dian 60) 5 year outcomes (%) were as follows:(see table).
All pcGVHDpts and 143 npcGVHDpts (76%) required systemic
therapy. Median time on treatment was 495 days compared with 286
days (p5 0.07), with 79% and 83% respectively being off immuno-
suppression by 3 years from onset of cGVHD. Despite a relatively
low incidence of aGVHD with this regimen about 60% of those
who do develop grade II-IV aGVHD and live100 days develop
pcGVHDwith a significantly higher risk ofNRM than other pts. Be-
cause of less relapse and equivalent NRM, OS and DFS are better in
pts with npcGVHD than those with no cGVHD. The challenge re-
mains to prevent aGVHD without sacrificing the GVM effect of
cGVHD.5 years outcomes in relation to cGVHD
npcGVHD(%) No cGVHD(%) pcGVHD(%) p value
OS 68*† 61* 50† *0.02, † 0.006
DFS 66*† 55* 42† *0.003,† 0.004
NRM 8* 12† 42*† *†\0.0001
Relapse 28* 39*† 28† *0.006, †0.02410
FLUTICASONE, AZITHROMYCIN, AND MONTELUKAST (FAM) THERAPY IN
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Background: Bronchiolitis obliterans syndrome (BOS) is a rare and
serious complication of allogeneic HCT, requiring long courses of
systemic corticosteroids that are often associated with adverse conse-
quences. Thus, novel therapies to reduce corticosteroid exposure
may be beneficial.
Hypothesis: Combined treatment with fluticasone, azithromycin
and montelukast (FAM), three agents with anti-inflammatory and
antifibrotic properties, all with low toxicity, will reduce the overall
six-month exposure to corticosteroids in BOS patients.
Methods: Between June 2008 and the present, we reviewed 8 pa-
tients who met NIH criteria for newly diagnosed BOS and were
treated with FAM therapy indefinitely and a 2-week pulse of high
dose (1 mg/kg/day) prednisone followed by a rapid taper. These
patients were compared with 14 historical controls identified
from a pre-existing database, who also met NIH criteria, and re-
ceived high dose prednisone therapy followed by a standard taper.
The total prednisone exposure (median values and interquartile
ranges) six months after diagnosis and interval change in FEV1 at
three, and/or six months after BOS diagnosis were compared.
FEV1 was reported as percent predicted with preference given to
post-bronchodilator values. FEV1 change was defined as change
in FEV1 from diagnosis to three or six months, depending on
pulmonary function test availability. Treatment failure was defined
as a decline in FEV1$ 10% and clinical worsening of symptoms
resulting in increase in prednisone dose within six months of
diagnosis.
Results: The median six month prednisone exposure for the FAM-
treated patients was 1819 mg [25th percentile5 0 mg; 75th percenti-
le5 4036 mg] compared to 7163 mg [25th percentile5 6551 mg;
75th percentile5 7829 mg] in the control group. The median
FEV1 change in the FAM group was 2% [25
th percentile5 -7%;
75th percentile5 4%] compared to 1% [25th percentile5 -4%;
75th percentile5 5%] in the control group. There was one treatment
failure in the FAM group (12%) compared to one in the control
group (7%).
Conclusions:The total six month prednisone exposure in a group of
eight patients treatedwith FAMtherapywas one quarter that of a ret-
rospective group of BOS patients who were treated with standard
prednisone therapy, with minimal change in median FEV1 in both
groups. FAM therapy may allow for less total exposure to corticoste-
roids and may avert some complications associated with steroid
therapy.411
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It is well recognized that T cells are the principal orchestrators
of graft versus host disease (GVHD). Historically, IFN-g produc-
ing Th1 cells have been implicated in the pathogenesis of acute
GVHD (aGVHD) whereas Th2 cells have been thought to be in-
volved in the pathogenesis of chronic GVHD (cGVHD). The re-
cent discovery of a distinct lineage of IL-17 producing Th17
cells, thought to be the major perpetrators in a number of inflam-
matory and autoimmune disorders, has prompted re-evaluation of
the Th1/Th2 paradigm of GVHD. Studies in IL-17 deficient
mice have shown conflicting results with IL-17 having both a pro-
tective or deleterious effect, whereas transplantation of purified
Th17 cells causes GVHD-related tissue damage with a predilection
for the skin and lungs. In this study we aimed to determine whether
Th17 cells play a role in the pathogenesis of human GVHD. 37
Table 1. Effects of Rifaximin onmarkers of inflammation andT
cell activation
Biomarker 1
Control
Mean (SE)
Treatment
Mean (SE)
Absolute
Treatment
Effects Mean
(95% CI)2
Relative
Treatment
Effect3 P value
IL-6 (pg/ml)
Baseline 0.98 (0.45) 2.55 (0.48)
Day 0 3.14 (0.51) 2.16 (0.51) -1.01 (-1.61, -0.41) 0.36 0.002
Day 15 10.58 (0.61) 8.35 (0.63) -0.89 (-1.98, 0.19) 0.41 0.10
sTNFR1 (pg/ml)
Baseline 1811 (1102) 1442 (1112)
Day 0 2243 (2243) 2097 (2097) 0.16 (-0.15, 0.47) 1.17 0.16
Day 15 3532 (3532) 3197 (1089) 0.13 (-0.21, 0.47) 1.15 0.45
sIL2R (ng/ml)
Baseline 5.35 (1.20) 3.54 (1.22)
Day 15 12.89 (1.25) 14.24 (1.27) 0.51 (-0.29, 1.31) 1.67 0.20
1Geometric means and standard errors, calculated by exponentiating
Poster Session II S309patients undergoing allogeneic SCT were included in this study.
Peripheral blood samples were taken prior to transplant and weekly
until day +100. To assess if Th17 cells are involved in cGVHD,
further samples were taken at 6 months and 1 year. Peripheral
blood mononuclear cells were stimulated with PMA/Ionomycin
and the lymphocytes were assessed for the intracellular expression
of IL-17 and IL-22. In parallel, plasma was analysed for IL-17 pro-
duction.
We found the frequency of IL-17 and IL-22 producing cells was
no higher in the 21 patients with aGVHD than the 16 patients
without GVHD either at the onset of, or one week prior to
aGVHD onset. Accordingly, the concentration of IL-17 in the
plasma did not differ between the two groups. IL-17 producing
cells and plasma levels were not elevated in patients who developed
cGVHD. To exclude that circulating Th17 cells were not identi-
fied because of marginalization from the blood into tissues, we iso-
lated T cells from the skin of patients with aGVHD (n5 5) and
cGVHD (n5 7) and tested them for their capacity to produce
Th17 associated cytokines. Interestingly, in patients with either
acute or chronic GVHD, we found a population of cells that pro-
duced IL-22 but not IL-17 or IFN-g. In accordance with this find-
ing, the expression of CCR6, a marker for Th17 cells, was
significantly lower in patients with GVHD. Our findings suggest
that in humans, Th17 do not appear to contribute to the patho-
physiology of GVHD, however in keeping with recent reports,
there appears to be a distinct IL-22 producing population that
may be important in skin pathology.the mean of the log transformed values.2Absolute treatment effect is
the absolute change from baseline to follow-up in the treatment group
minus the absolute change in the control group from the mixed effects
model. 3Relative treatment effect is defined as: (treatment group follow-
up/treatment group baseline)/(Placebo group follow-up/Placebo group
baseline). The interpretation of the relative effect is similar to that of
the odds ratio.412
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Bacterial translocation across damaged gut mucosa is critical in
the pathogenesis of acute graft versus host disease (AGVHD).
Pre-clinical research has demonstrated that mitigating the effects
of gut flora prevents AGVHD. Rifaximin is a broad acting, mini-
mally absorbed oral antibiotic, which has been shown to be effec-
tive in inflammatory bowel disease. We conducted a pilot trial to
test the hypothesis that rifaximin would abrogate systemic inflam-
mation and resultant T cell activation in allogeneic transplant re-
cipients. Twenty adult and pediatric ($12 years) allogeneic blood
and marrow transplant recipients who received myeloablative con-
ditioning were enrolled. Rifaximin (400 mg bid) was started on day
-10 and continued through day 30. Enzyme-linked immunosorbent
assays were performed on plasma samples at baseline, day 0 (pre-
transplant) and day 15 to measure levels of markers of inflamma-
tion, soluble TNF receptor 1 (sTNFR1) and interleukin 6 (IL-6),
and donor T cell activation, soluble IL-2 receptor (sIL-2R). A his-
torical control group (n5 24) was formed from subjects enrolled
on a previously conducted study. There were no significant differ-
ences between the 2 groups in conditioning regimen, proportion of
alternative donors or GVHD prophylaxis. The treatment group
was significantly younger (median age 17.3 vs. 38.8 years) and in-
cluded significantly more cord blood transplants (7 (3 single unit
and 4 double unit) vs. 0). The mean percentage of rifaximin doses
successfully administered was 86.2%. There were no serious ad-
verse events attributed to rifaximin. The incidences of grade 2-4
AGVHD, grade 3-4 AGVHD and stage 1-4 gastrointestinal
AGVHD were similar between the 2 groups (treatment vs. control:
69% vs. 58% p5 0.63, 34% vs. 22% p5 0.50 and 58% vs. 45%
p5 0.58, respectively). Mean IL-6 concentration decreased by
64% in the treatment group relative to the control group by day
0 (p5 0.002) (table 1). At day 15, the relative change was 59%
(p5 0.1). sTNFR1 and sIL-2R did not change in the treatment
group relative to the control group. Controlling for age and donor
did not alter the results. This pilot study demonstrates that admin-
istering rifaximin to prevent AGVHD is safe and feasible. Rifaxi-
min appears to limit inflammation stemming from bacterialtranslocation as suggested by its effect on IL-6 levels, but its
anti-inflammatory effect is insufficient to prevent activation of
donor T cells; therefore, it may not be suitable for GVHD
prophylaxis.413
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In animal models, regulatory T cells (Treg) have been demon-
strated to control autoimmune inflammation and prevent acute
graft versus host disease (AGVHD), but the role of Treg in
chronic GVHD (CGVHD) remains unknown. In a natural history
study of CGVHD patients (NCI 04-C-0281), we assessed the fre-
quency and phenotype of FoxP3 + T cells in blood and in affected
tissues. We used immunofluorescent staining for FoxP3 and con-
focal microscopy to assess Treg in tissue biopsies from patients
with oral and lichenoid cutaneous CGVHD. Although no sequen-
tial biopsies were examined, the consistent observation was that
the number of FoxP3+ cells was increased in severely affected
oral mucosa and lichenoid skin compared to clinically uninvolved
tissue, but remained in proportion to the total CD3 + T cell pop-
ulation. Using multiparameter flow cytometry, we determined that
the frequency of FoxP3+ cells among circulating CD4 + T cells did
not differ in CGVHD patients compared to normal donors, al-
though the absolute numbers of total CD4 and Treg were lower
than normal. We assessed the origins of Treg cells after transplan-
tation by comparing the frequency of naive (CCR7 + CD45RA+),
thymic-matured ‘natural’ Treg and peripherally expanding (Ki-
67+) Treg. The decline in the frequency of naive CD4 T-cells in
CGHVD patients was more severe in FoxP3 + CD4 than in
FoxP3- CD4 (106 2% vs 276 3%; P\0.00001), whereas the fre-
quency of cells in cycle was increased in FoxP3 + CD4 cells (196 2
vs 76 1%, P\0.00001). This result is consistent with a greater
impact of transplantation and CGVHD on thymic-dependent gen-
eration of Treg than of FoxP3- CD4 cells and a concomitant
increase in proliferative expansion. These data suggest that Treg
populations can recover to frequencies proportional to total
CD4 cells in CGVHD patients and can move into inflamed tis-
sues, but that reconstitution is primarily by peripheral expansion
rather than thymopoiesis.
